SOW
CRSP icon

State of Wyoming’s CRISPR Therapeutics CRSP Stock Holding History

State of Wyoming’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-109
Closed -$7K – 1603
2022
Q2 		$7K Sell
109
-933
-90% -$54.9K ﹤0.01% 1684
2022
Q1 		$65K Buy
1,042
+206
+25% +$12.9K 0.03% 895
2021
Q4 		$63K Buy
+836
New +$73K 0.03% 974

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State of Wyoming's CRSP Position: Q3 2022 in Review

State of Wyoming sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 109 shares — an estimated $7K sold.

State of Wyoming first reported a position in CRSP in Q4 2021 and held it in 3 quarters. The position peaked at $65K in Q1 2022. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

  • State of Wyoming reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • State of Wyoming sold 109 CRISPR Therapeutics shares in Q3 2022, an estimated $7K.
  • State of Wyoming first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 3 quarters.
  • State of Wyoming's CRISPR Therapeutics position peaked at $65K in Q1 2022.
  • 436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on State of Wyoming's 13F filing for Q3 2022, filed 14 Nov 2022.